Generic pharmaceutical company Hikma Pharmaceuticals PLC reported on Monday that the US District Court for the District of Nevada has ruled that its generic version of Amarin Corporation's Vascepa (icosapent ethyl) 1 gm capsules does not infringe six US Patents, as asserted by Amarin, because the asserted claims of these patents were held to be invalid.
Following the US Court's favourable ruling, Hikma said it is working closely with the US Food and Drug Administration (FDA) to acquire approval for its Abbreviated New Drug Application (ANDA) for its generic version of Vascepa. The company is evaluating its options for launching the product following FDA approval, including an at-risk launch in the event the District Court's decision is appealed.
Vascepa is a prescription medicine that is indicated, in part, as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. According to IQVIA, US sales of Vascepa were USD919m in the 12 months ending February 2020.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT